Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Sutro Biopharma, Inc. has received a consensus rating of "Hold" from analysts, with one sell rating, four holds, and two buy ratings reported.
• The stock has been downgraded by Wells Fargo to a target price of $3.00, while Piper Sandler upgraded it to a target of $2.00.
• Sutro Biopharma's stock is currently trading at $0.83, significantly down from its 12-month high of $4.60, with a market cap of $70.22 million.

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) have earned a consensus rating of "Hold" from the seven analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $4.4667.

Several equities analysts recently issued reports on the stock. Wells Fargo & Company dropped their target price on shares of Sutro Biopharma from $4.00 to $3.00 and set an "equal weight" rating on the stock in a report on Tuesday, August 12th. Piper Sandler upgraded shares of Sutro Biopharma from a "neutral" rating to an "overweight" rating and set a $2.00 target price on the stock in a report on Monday, June 16th. Finally, Wall Street Zen raised shares of Sutro Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday, September 13th.

Institutional Investors Weigh In On Sutro Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the stock. ProShare Advisors LLC increased its stake in Sutro Biopharma by 74.3% in the fourth quarter. ProShare Advisors LLC now owns 26,961 shares of the company's stock valued at $50,000 after purchasing an additional 11,494 shares in the last quarter. Catalyst Funds Management Pty Ltd bought a new stake in Sutro Biopharma in the second quarter valued at $27,000. Cerity Partners LLC bought a new stake in Sutro Biopharma in the first quarter valued at $25,000. Vontobel Holding Ltd. increased its stake in Sutro Biopharma by 100.0% in the first quarter. Vontobel Holding Ltd. now owns 50,000 shares of the company's stock valued at $33,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Savant Capital LLC bought a new stake in Sutro Biopharma in the second quarter valued at $37,000. 96.99% of the stock is owned by institutional investors.

Sutro Biopharma Stock Down 6.9%

STRO stock opened at $0.83 on Wednesday. The firm has a market cap of $70.22 million, a price-to-earnings ratio of -0.33 and a beta of 1.57. Sutro Biopharma has a 12-month low of $0.52 and a 12-month high of $4.60. The company's fifty day simple moving average is $0.87 and its 200 day simple moving average is $0.84.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.25. The business had revenue of $63.74 million for the quarter, compared to analyst estimates of $14.55 million. Sutro Biopharma had a negative net margin of 201.32% and a negative return on equity of 852.70%. Research analysts expect that Sutro Biopharma will post -2.92 earnings per share for the current year.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.